CSPC PHARMA (01093) issues a profit warning, expecting a decrease of approximately 26% in the annual net profit attributable to shareholders compared to the previous year.
Sinopharm Group (01093) announced that it expects the group to have... as of December 31, 2024 for the fiscal year.
CSPC PHARMA (01093) announced that it is expected the group's attributable profit to owners for the year ending December 31, 2024 will decrease by approximately 26% compared to the year ending December 31, 2023, which was approximately RMB 5.873 billion.
It is reported that the decrease in the group's attributable profit to owners for the year ending December 31, 2024 is mainly due to a decrease in revenue from the pharmaceutical business by about 7% compared to the year ending December 31, 2023. The main reasons are as follows:
(1) The prices of the two products, Jin You Li and Duo Mei Su, were reduced by approximately 58% and 23% respectively in the "3+N" alliance drug centralized procurement in the Beijing-Tianjin-Hebei region. As the centralized procurement started to be implemented in various provinces in March 2024, the sales of these two products significantly declined. As a result, the revenue in the oncology treatment area decreased by about 28% for the year ending December 31, 2024 compared to the year ending December 31, 2023; and
(2) Xuan Ning was not selected in the national eighth batch centralized procurement in 2023, leading to a significant impact on its sales in hospitals strictly following the centralized procurement. Consequently, the revenue in the cardiovascular treatment area decreased by about 15% for the year ending December 31, 2024 compared to the year ending December 31, 2023.
Related Articles

Huachu Securities: Shunfeng (06936) continues to lead in the volume growth rate in June, pay attention to investment opportunities in the express delivery sector under the "anti-inner loop" trend.

Guosen: How to make absolute return investments in a low interest rate environment?

Preview of new stocks in the US stock market | Industry anti-involvement helps to repair the fundamentals, how does New Subee Optoelectronics (XZ.US) break into the top tier of the industry?
Huachu Securities: Shunfeng (06936) continues to lead in the volume growth rate in June, pay attention to investment opportunities in the express delivery sector under the "anti-inner loop" trend.

Guosen: How to make absolute return investments in a low interest rate environment?

Preview of new stocks in the US stock market | Industry anti-involvement helps to repair the fundamentals, how does New Subee Optoelectronics (XZ.US) break into the top tier of the industry?

RECOMMEND

For the Third Consecutive Month, China Reduces U.S. Treasury Holdings by $900 Million in May, While Japan and the United Kingdom Increase Holdings
18/07/2025

Tariff-Driven Inflation Arrives with Delay as U.S. Consumers Begin to Feel the Initial Pinch
18/07/2025

Multiple Countries in High-Stakes Talks with the U.S.; EU Considers Invoking “Anti-Coercion Tool” as U.S. Plans Unified Tariffs on 150 Nations
18/07/2025